PURPOSE Sarcopenia is increasingly recognized as an independent risk factor for poor outcomes in patients undergoing hematopoietic stem cell transplantation (HSCT), and it is a potentially modifiable factor. The purpose of the present systematic review and meta-analysis is to summarize and integrate current evidence in this field. METHODS We searched EMBASE, MEDLINE, and Cochrane DSR through Ovid and PubMed websites to identify relevant studies. Studies evaluated sarcopenia before HSCT and reported associations between sarcopenia and post-transplant outcomes were included. Two authors independently applied eligibility criteria, assessed quality, and extracted data. Odds ratio (OR) and their 95% confidence intervals (CIs) were pooled to examine the association between sarcopenia and post-transplant outcomes by using the review manager 5.3 software. RESULTS Seven retrospective cohort studies met our inclusion criteria. The overall quality of studies was low to moderate. Sarcopenia was associated with higher non-relapse mortality [odds ratio (OR) 1.97; 95% CI 1.45, 2.68; P < 0.0001; I2 = 0%] and shorter overall survival [odds ratio (OR) 0.44; 95% CI 0.26, 0.75; P = 0.002; I2 = 65%] in patients undergoing HSCT. CONCLUSIONS Clinicians could use sarcopenia to balance the risks and benefits of transplantation as early as possible; in addition, interventions can be used to prevent sarcopenia and improve physical function and quality of life. Well-designed, prospective, and large-scale clinical studies are needed to consolidate the evidence.

中文翻译：

---

少肌症在进行造血干细胞移植的血液系统恶性肿瘤幸存者中的预后价值：系统评价和荟萃分析。

目的越来越多的肌肉减少症被认为是造血干细胞移植（HSCT）患者预后不良的独立危险因素，并且它是潜在的可改变因素。本系统综述和荟萃分析的目的是总结和整合该领域的最新证据。方法我们通过Ovid和PubMed网站搜索EMBASE，MEDLINE和Cochrane DSR，以鉴定相关研究。研究评估了HSCT之前的肌肉减少症，并报道了肌肉减少症与移植后结局之间的关联。两位作者独立应用了资格标准，评估了质量并提取了数据。使用Review Manager 5.3软件汇总赔率（OR）和其95％置信区间（CI），以检查肌肉减少症与移植后结果之间的关联。结果七项回顾性队列研究符合我们的纳入标准。研究的总体质量是低到中等。肌肉减少症与较高的非复发死亡率相关[比值比（OR）1.97；95％CI 1.45，2.68; P <0.0001; I2 = 0％]和较短的总生存期[赔率（OR）0.44；95％CI 0.26，0.75; P = 0.002; HSCT患者中I2 = 65％]。结论临床医生可以使用肌肉减少症来尽早平衡移植的风险和益处。此外，可以采用干预措施来预防肌肉减少症并改善身体机能和生活质量。需要精心设计，前瞻性和大规模的临床研究来巩固证据。肌肉减少症与较高的非复发死亡率相关[比值比（OR）1.97；95％CI 1.45，2.68; P <0.0001; I2 = 0％]和较短的总生存期[赔率（OR）0.44；95％CI 0.26，0.75; P = 0.002; HSCT患者中I2 = 65％]。结论临床医生可以使用肌肉减少症来尽早平衡移植的风险和益处。此外，可以采用干预措施来预防肌肉减少症并改善身体机能和生活质量。需要精心设计，前瞻性和大规模的临床研究来巩固证据。肌肉减少症与较高的非复发死亡率相关[比值比（OR）1.97；95％CI 1.45，2.68; P <0.0001; I2 = 0％]，总生存期较短[赔率（OR）为0.44；95％CI 0.26，0.75; P = 0.002; HSCT患者中I2 = 65％]。结论临床医生可以使用肌肉减少症来尽早平衡移植的风险和益处。此外，可以采用干预措施来预防肌肉减少症并改善身体机能和生活质量。需要精心设计，前瞻性和大规模的临床研究来巩固证据。结论临床医生可以使用肌肉减少症来尽早平衡移植的风险和益处。此外，可以采用干预措施来预防肌肉减少症并改善身体机能和生活质量。需要精心设计，前瞻性和大规模的临床研究来巩固证据。结论临床医生可以使用肌肉减少症来尽早平衡移植的风险和益处。此外，可以采用干预措施来预防肌肉减少症并改善身体机能和生活质量。需要精心设计，前瞻性和大规模的临床研究来巩固证据。